Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 204

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS

Open access
Benatar, Michael, Zhang, Lanyu, Wang, Lily, Granit, Volkan, Statland, Jeffrey, Barohn, Richard, Swenson, Andrea, Ravits, John, Jackson, Carlayne, Burns, Ted M., Trivedi, Jaya, Pioro, Erik P., Caress, James, Katz, Jonathan, McCauley, Jacob L., Rademakers, Rosa, Malaspina, Andrea, Ostrow, Lyle W., Wuu, Joanne, Hussain, Sumaira, Cooley, Anne, Li, Yindi, Wallace, Marielle, Steele, Julie, Hernandez, Jessica P, Medina, Jessica, Paredes, Maria Elena, Manso, Ashley, Ravelo, Natalia, Levy, Wendy, Whitehead, Patrice, Zuchner, Stephan, Pasnoor, Mamatha, Jawdat, Omar, Jabari, Duaa, Farmakidis, Constantine, Glenn, Melanie, Dimachkie, Mazen M, Herbelin, Laura, Tanui, Hellen, Anderson, Sherri, Walker, Michaela, Liu, Tina, McCally, Ayla, Heim, Andrew, Currence, Melissa, Harness, Yolanda, Sieren, Jeri, Gibson, Emilee, Gutierrez, Gil, Bussey, Danielle, Previte, Rose, Kittrell, Pamella, Joshi, Amruta, Conger, Amy, Hastings, Debbie, Caristo, Irys, Marandi, Mozhdeh, Carty, Simon, Taylor, J Paul, Wu, Gang, Rampersaud, Evadnie, Schule, Rebecca, Blitterswijk, Marka van · 2020 · Neurology

Abstract

OBJECTIVE: To identify preferred neurofilament assays and clinically validate serum neurofilament light (NfL) and phosphorylated neurofilament heavy (pNfH) as prognostic and potential pharmacodynamic biomarkers relevant to amyotrophic lateral sclerosis (ALS) therapy development. METHODS: In this prospective, multicenter, longitudinal observational study of patients with ALS (n = 229), primary lateral sclerosis (n = 20), and progressive muscular atrophy (n = 11), biological specimens were collected, processed, and stored according to strict standard operating procedures (SOPs). Neurofilament assays were performed in a blinded manner by independent contract research organizations. RESULTS: For serum NfL and pNfH measured using the Simoa assay, there were no missing data (i.e., technical replicates below the lower limit of detection were not encountered). For the Iron Horse and Euroimmun pNfH assays, such missingness was encountered in ∼4% and ∼10% of serum samples, respectively. Mean coefficients of variation for NfL in serum and CSF were both ∼3%. Mean coefficients of variation for pNfH in serum and CSF were ∼4%-5% and ∼2%-3%, respectively, in all assays. Baseline serum NfL concentration, but not pNfH, predicted the future Revised ALS Functional Rating Scale (ALSFRS-R) slope and survival. Incorporation of baseline serum NfL into mixed effects models of ALSFRS-R slopes yields an estimated sample size saving of ∼8%. Depending on the method used to estimate effect size, use of serum NfL (and perhaps pNfH) as pharmacodynamic biomarkers, instead of the ALSFRS-R slope, yields significantly larger sample size savings. CONCLUSIONS: Serum NfL may be considered a clinically validated prognostic biomarker for ALS. Serum NfL (and perhaps pNfH), quantified using the Simoa assay, has potential utility as a pharmacodynamic biomarker of treatment effect.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000009559

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 204

Metadata

Authors
Benatar, M., Zhang, L., Wang, L., Granit, V., Statland, J., Barohn, R., Swenson, A., Ravits, J., Jackson, C., Burns, T. M., Trivedi, J., Pioro, E. P., Caress, J., Katz, J., McCauley, J. L., Rademakers, R., Malaspina, A., Ostrow, L. W., Wuu, J., Hussain, S., Cooley, A., Li, Y., Wallace, M., Steele, J., Hernandez, J. P., Medina, J., Paredes, M. E., Manso, A., Ravelo, N., Levy, W., Whitehead, P., Zuchner, S., Pasnoor, M., Jawdat, O., Jabari, D., Farmakidis, C., Glenn, M., Dimachkie, M. M., Herbelin, L., Tanui, H., Anderson, S., Walker, M., Liu, T., McCally, A., Heim, A., Currence, M., Harness, Y., Sieren, J., Gibson, E., Gutierrez, G., Bussey, D., Previte, R., Kittrell, P., Joshi, A., Conger, A., Hastings, D., Caristo, I., Marandi, M., Carty, S., Taylor, J. P., Wu, G., Rampersaud, E., Schule, R., & Blitterswijk, M. V.
Venue
Neurology
Published
2020-07-07
Volume
95
Issue
1
Pages
e59-e69
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W3022230889
Cited by
204
References
2
FWCI
10.39
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. https://app.cochat.ai/papers/10.1212/wnl.0000000000009559
The paper
Benatar, M., Zhang, L., Wang, L., Granit, V., Statland, J., Barohn, R., Swenson, A., Ravits, J., Jackson, C., Burns, T. M., Trivedi, J., Pioro, E. P., Caress, J., Katz, J., McCauley, J. L., Rademakers, R., Malaspina, A., Ostrow, L. W., Wuu, J., . . . Blitterswijk, M. V. (2020). Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology. https://doi.org/10.1212/wnl.0000000000009559

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.